MIT Technology Review has published its latest edition of The Download, its daily technology newsletter, spotlighting two developments worth broader attention: a new cohort of young biotech innovators identified through the publication's long-running 35 Innovators Under 35 list, and emerging work around producing steel at lower cost and with a reduced environmental footprint.
Neither of these is a minor footnote. Taken together, they touch on two of the most consequential industrial challenges of the coming decades — the transformation of life sciences through a younger generation of researchers, and the decarbonization of one of the world's most emissions-heavy manufacturing sectors. That they appear side by side in a single newsletter dispatch is itself a signal of where serious technology attention is being directed right now.
The 35 Innovators Under 35 list has been a fixture of MIT Technology Review's editorial calendar for decades. Its alumni include researchers and entrepreneurs who went on to found significant companies, lead major laboratory breakthroughs, and reshape entire fields. The list functions less as a simple honor roll and more as an early-warning system for where scientific and commercial energy is accumulating. In biotech specifically, the past several years have seen the list reflect a dramatic broadening of what the field even means. It once connoted primarily pharmaceutical development and medical devices. Today it spans synthetic biology, computational protein design, cell and gene therapies, agricultural biotechnology, and the engineering of entirely new biological systems. The researchers appearing on the current list, whoever they are, are likely working somewhere in this expanded terrain, and the likely reading is that their selection reflects MIT Technology Review's judgment about which subdisciplines are generating the most genuine momentum rather than the most hype.
The biotech industry itself is navigating a complicated moment. After a funding surge during the pandemic years that sent valuations skyward and drew enormous speculative capital into early-stage ventures, the sector has spent much of the subsequent period in a painful correction. Many companies that raised money on the promise of platform technologies have struggled to demonstrate clinical or commercial results. Against that backdrop, the significance of highlighting individual researchers under 35 is partly corrective — it redirects attention from company valuations and deal flow back toward the underlying science and the people doing it. Talent, not capital, is what ultimately moves biology forward, and that argument has particular force during a period when the capital environment has grown more skeptical.
The steel story operates on a different register but is no less urgent. Steel production is responsible for a substantial share of global industrial carbon emissions, owing primarily to the traditional blast furnace process, which relies heavily on coal as both a fuel and a chemical reducing agent. For years, the pathway to cleaner steel has been theoretically understood — using hydrogen or electrolysis-based methods to strip oxygen from iron ore without burning fossil fuels — but the economics have remained prohibitive. If the work MIT Technology Review is flagging suggests that cost barriers are beginning to fall, even incrementally, the implications are significant. The construction sector, the automotive supply chain, the energy infrastructure buildout required for the clean energy transition itself — all of it runs on steel, and all of it carries embedded emissions that are very difficult to address without changing how the metal is made. A cheaper, cleaner production method would not merely be an environmental win but a competitive and geopolitical one, given how central steel capacity is to industrial strategy in major economies.
The consequences of progress in either of these areas are distributed unevenly. In biotech, the beneficiaries of a strong new generation of researchers are, eventually, patients — but also the investors and institutions positioned early in the companies those researchers build. In green steel, the stakes are higher and more diffuse: energy companies, mining operations, national governments, and the global climate accounting all have something riding on whether low-emissions steel becomes economically viable at scale within the next decade or two.
What to watch for next is reasonably clear in both cases. In biotech, the names on the 35 Under 35 list are worth tracking not just as individuals but as indicators of which institutions — universities, research hospitals, national labs — are producing the most promising early-career talent, and which areas of biology they are working in. In steel, the question is whether any announced processes or cost reductions have moved beyond laboratory demonstration into pilot or commercial scale, since that transition has historically been where green materials technologies stall. The gap between a promising result and an economically deployable one remains the central problem, and any credible evidence that gap is closing in steel production would be news of genuine consequence.
